Oral Sildenafil in the Treatment of Erectile Dysfunction

The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction

“…Whereas baseline IIEF scores of spinal cord injured patients in this study resembled those of diabetic patients in the Rendell et al diabetes study 21 (2.0 vs 1.8 for Q3; 1.5 vs 1.5 for Q4), post-treatment scores in the spinal-cord injury group more closely resembled those of the USA and European studies with patients of mixed etiology. 15,16 Event-log data for the spinal cord patients again corroborated the overall pattern of IIEF results obtained. Eighty per cent of patients reported improved intercourse with sildenafil vs 10% with placebo.…”

“…Event log data showed a similar pattern of results to IIEF scores, with 61% of patients in the active treatment group reporting at least one successful intercourse attempt, vs 22% of patients receiving placebo. A comparison of IIEF scores in these patients with the first two USA studies in patients with mixed etiologies 15 indicates that the baseline scores of patients with diabetes trended lower (that is, more dysfunctional) for both Q3 (1.8 vs 2.0) and Q4 (1.5 vs 1.7). Similarly, although significant treatment effects were observed in all three studies, mean estimates of post-treatment IIEF scores for patients with diabetes were lower on both Q3 (3.9 vs 3.2) and Q4 (3.6 vs 2.9).…”

“…15 One of these studies consisted of a double-blind, placebo-controlled, fixed dose trial of 532 men with ED. Patients were randomly assigned to receive placebo, 25, 50, or 100 mg of sildenafil for 24 weeks.…”

“…Patients for both studies were aged 20 -87 and had ED of mixed organic and psychogenic etiologies. As shown in Table 1, mean scores on Q3 (ability to achieve penetration) and Q4 (ability to maintain penetration) in the two studies 15 increased from 2.0 (Q3) and 1.5 (Q4) at baseline to 4.0 (Q3) and 3.9 (Q4) at 100 mg in the fixed-dose study, and from 2.0 (Q3) and 1.5 (Q4) at baseline to 3.9 (Q3) and 3.6 (Q4) in the flexible-dose study. Corresponding scores for placebo were 2.2 and 2.1 in the fixed dose study, and 2.3 and 1.8 in the flexible dose study.…”

Penile prosthesis implantation: past, present and future

“…5,6 The third in 1998 was the introduction of sildenafil citrate, the first significantly effective oral therapy for ED. 7 The attractiveness of oral therapy with the phosphodiesterase type 5 inhibitors and the widespread publicity concerning their use has made ED a household concept. While first line oral therapies are helpful for many men with ED, they are not helpful for all.…”